MedTrace Logo

Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy

NCT01727973 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-12-10

No results posted yet for this study

Summary

The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy (GO).

Conditions

  • Graves Ophthalmopathy
  • Graves Disease
  • Eye Diseases
  • Thyroid Diseases
  • Endocrine System Diseases
  • Eye Diseases, Hereditary
  • Hyperthyroidism
  • Autoimmune Diseases
  • Immune System Diseases

Interventions

DRUG

Doxycycline

Tab. Doxycycline 50 mg PO per day for 12 weeks

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Dan Liang, MD · Zhongsh Ophthalmic Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01727973 on ClinicalTrials.gov